Anaesthesia Choice for Creation of Arteriovenous Fistula (ACCess) study protocol : a randomised controlled trial comparing primary unassisted patency at 1 year of primary arteriovenous fistulae created under regional compared to local anaesthesia.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Macfarlane Alan Jr, Kearns Rachel J, Clancy Marc James, Kingsmore David, Stevenson Karen, Jackson Andrew, Mark Patrick, Aitken Margaret, Moonesinghe Ramani, Vindrola-Padros Cecilia, Gaianu Lucian, Pettigrew Gavin, Motallebzadeh Reza, Karydis Nikolaos, Vesey Alex, Singh Rita, Muniraju Thalakunte, Suttie Stuart, McConnachie Alex, Wetherall Kirsty, El-Boghdadly Kariem, Hogg Rosemary, Thomson Iain, Nangalia Vishal, Aitken Emma, Access collaborative group, ACCess collaborative group
Аннотация
METHODS AND ANALYSIS: The Anaesthesia Choice for Creation of Arteriovenous Fistula (ACCess) study is a multicentre, observer-blinded RCT comparing primary radiocephalic/brachiocephalic AVF created under regional versus LA. The primary outcome is primary unassisted AVF patency at 1 year. Access-specific (eg, stenosis/thrombosis), patient-specific (including health-related quality of life) and safety secondary outcomes will be evaluated. Health economic analysis will also be undertaken.
ETHICS AND DISSEMINATION: The ACCess study has been approved by the West of Scotland Research and ethics committee number 3 (20/WS/0178). Results will be published in open-access peer-reviewed journals within 12 months of completion of the trial. We will also present our findings at key national and international renal and anaesthetic meetings, and support dissemination of trial outcomes via renal patient groups.
TRIAL REGISTRATION NUMBER: ISRCTN14153938.
SPONSOR: NHS Greater Glasgow and Clyde GN19RE456, Protocol V.1.3 (8 May 2021), REC/IRAS ID: 290482.